# HEALEY ALS Platform Trial Regimen I enrolment completed – Topline results for NUZ-001 accelerated to Q2 CY2027

- Link: https://www.thailand-business-news.com/pr-news/healey-als-platform-trial-regimen-i-enrolment-completed-topline-results-for-nuz-001-accelerated-to-q2-cy2027
- Published: 2026-07-17T10:48:00+07:00
- Author: PR Newswire

◦ **250 participants enrolled in less than five months from first participant dosing,
   representing the fastest site activation and enrolment in the HEALEY ALS Platform
   Trial so far**
 ◦ **Anticipated topline efficacy and safety results for NUZ-001 now expected in
   late Q2 CY2027**
 ◦ **Completion of recruitment materially de-risks execution of Neurizon’s lead 
   late-stage clinical program**
 ◦ **Reflects strong recruitment and effective execution across the HEALEY ALS Platform
   Trial network**
 ◦ **Participants now progressing through the planned 36-week randomised treatment
   period**

MELBOURNE, Australia, 16 July 2026 /PRNewswire/ — Neurizon® Therapeutics Limited(
ASX: NUZ; OTCQB: NUZTF) ("Neurizon" or "the Company"), a late-stage clinical biotechnology
company dedicated to advancing innovative treatments for neurodegenerative diseases,
is pleased to advise that enrolment has been completed in Regimen I of the Phase
2/3 HEALEY ALS Platform Trial evaluating the Company’s lead investigational therapy
NUZ-001 for the treatment of amyotrophic lateral sclerosis (ALS).

Neurizon advises that the final participant has completed their baseline visit and
commenced treatment, completing enrolment into Regimen I. Reflecting the rapid pace
of recruitment, the Company now expects to report topline efficacy and safety results
in late Q2 CY2027, earlier than previously anticipated.

Completion of enrolment, together with the earlier anticipated timing of the topline
results readout, further demonstrates the continued advancement of the late-stage
clinical development program for NUZ-001 for the treatment of ALS. Regimen I completed
enrolment in less than five months from first participant dosing, becoming the fastest
regimen to activate sites and complete enrolment in the HEALEY ALS Platform Trial,
even after the planned sample size expansion from 160 to 240 participants in response
to strong recruitment momentum.

This achievement reflects the strength of recruitment across the HEALEY ALS Platform
Trial network, one of the world’s leading ALS clinical trial initiatives, the operational
efficiencies introduced under the trial’s next generation master protocol, and the
commitment of investigators, research coordinators and clinical site teams across
the United States. 

Neurizon sincerely acknowledges every person living with ALS and their families 
who has chosen to participate in this research, recognising that their commitment
is fundamental to advancing clinical research and the development of potential new
treatment options for the ALS community.

Participants will now continue through the 36-week Randomised Controlled Trial phase
before entering the 36-week Active Treatment Extension phase, with the Company’s
focus centred on continued execution ahead of the anticipated topline readout in
late Q2 CY2027.

**Interim Executive Chairman, Mr Sergio Duchini said: **"Completion of enrolment
represents a major milestone in the clinical development of NUZ-001. Importantly,
the rapid completion of recruitment has enabled the anticipated timing of topline
efficacy and safety results to be accelerated into late Q2 CY2027, bringing forward
an important value inflection point for Neurizon and our shareholders.

On behalf of the Company, I would like to sincerely thank every person living with
ALS and their families who chose to participate in this trial. Their willingness
to contribute to research despite the immense challenges of this disease is inspiring
and is fundamental to advancing the development of new treatment options for people
living with ALS.

I would also like to acknowledge the outstanding work of the HEALEY ALS Platform
Trial team, investigators, research coordinators and clinical site teams whose expertise,
collaboration and commitment have made this achievement possible.

With recruitment now complete, our focus turns to delivering the study with the 
same operational discipline that has characterised the program to date. We look 
forward to advancing NUZ-001 through clinical development and towards the anticipated
topline efficacy and safety results."

**Director of the Sean M. Healey & AMG Center and Executive Director of the Mass
General Brigham Neuroscience Institute, Merit Cudkowicz, MD, MSc said**: "We are
grateful to everyone who helped complete enrolment in Regimen I in such a short 
amount of time. We believe strongly in importance of speed, efficiency and high 
quality in clinical trials. Our patients tell us that the ALS clock is faster and
we need to work collaboratively to develop treatments sooner. This is one of the
guiding principles of the Healey ALS Platform Trial, Next Generation. The rapid 
speed of enrolment in this regimen is a testament to the hard work of participants
and their families and study staff across all the participating NEALS sites, as 
well as to the optimised Platform Trial infrastructure."

**About the HEALEY ALS Platform Trial: **

The HEALEY ALS Platform Trial (ClinicalTrials.gov identifier: NCT04297683) is a 
multicentre, double-blind, placebo controlled adaptive Phase 2/3 clinical trial 
conducted by the Sean M. Healey & AMG Center for ALS at Mass General Brigham in 
the United States (US), created in partnership with the Network of Excellence for
ALS (NEALS). Entry into the HEALEY ALS Platform Trial is competitive, with drug 
candidates reviewed and selected by expert committees based on scientific merit 
and evidence of potential benefit in ALS. The goal of the HEALEY ALS Platform Trial
is to accelerate the development of potential new ALS therapies.

-ENDS-

This announcement has been authorised for release by the Board of Neurizon Therapeutics
Limited.

**About Neurizon Therapeutics Limited**

Neurizon Therapeutics Limited (ASX: NUZ) is a late-stage clinical biotechnology 
company dedicated to advancing treatments for neurodegenerative diseases. Neurizon
is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which 
is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate
access to effective ALS treatments for patients while exploring the potential of
NUZ-001 for broader neurodegenerative applications. Through international collaborations
and rigorous clinical programs, Neurizon is dedicated to creating new horizons for
patients and families impacted by complex neural disorders. NUZ-001 is an investigational
product and is not approved for commercial use in any jurisdiction.

**Neurizon Investor Hub**

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement
or other aspects concerning Neurizon.
This platform offers an opportunity to submit
questions, share comments, and view video summaries of key announcements.To access
Neurizon Investor Hub please visit [https://investorhub.neurizon.com](https://investorhub.neurizon.com/)
Neurizon® is a registered trademark of Neurizon Therapeutics Limited.

 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [HEALEY ALS Platform Trial Regimen I enrolment completed – Topline results for NUZ-001 accelerated to Q2 CY2027 ](http://www.prnasia.com/story/archive/5006787_CN06787_0?rand=184833)
